STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Acquires 34,296 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 34,296 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was purchased at an average price of $17.44 per share, with a total value of $598,122.24. Following the completion of the purchase, the insider now directly owns 12,319,691 shares of the company’s stock, valued at approximately $214,855,411.04. This trade represents a 0.28 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The shares were acquired at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The stock was bought at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The stock was bought at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

STAAR Surgical stock opened at $17.57 on Friday. STAAR Surgical has a one year low of $13.50 and a one year high of $52.68. The company has a 50-day simple moving average of $19.52 and a 200-day simple moving average of $25.32. The firm has a market capitalization of $866.64 million, a P/E ratio of -42.85 and a beta of 0.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Resona Asset Management Co. Ltd. acquired a new position in shares of STAAR Surgical during the fourth quarter worth approximately $36,411,000. Vanguard Group Inc. raised its stake in STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after acquiring an additional 319,441 shares in the last quarter. Yunqi Capital Ltd boosted its position in STAAR Surgical by 48.9% during the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock worth $18,640,000 after acquiring an additional 252,113 shares during the period. JPMorgan Chase & Co. grew its stake in shares of STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 172,779 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of STAAR Surgical by 25.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock valued at $20,728,000 after purchasing an additional 171,046 shares during the period. Institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Piper Sandler decreased their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 12th. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $45.00 to $17.00 in a report on Wednesday, February 12th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $17.00 price target on shares of STAAR Surgical in a report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, STAAR Surgical currently has an average rating of “Hold” and a consensus price target of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.